A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
← catalyst calendarNCT07215702 · readout in 176 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
124estimated
Sites
72
Countries
Argentina, Belgium, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-10 | actual | When the study began enrolling |
| Primary completion | 2027-02-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-11 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sepsis
- Acute Kidney Injury
Interventions
- Drug: AZD4144
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFArea Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl).
measured During the treatment period.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed